Competitive ChallengesAnalyst reiterates Underperform and $11 price objective on, in their view, an overvalued long-term market opportunity for Briumvi with key challenges to competitive pillars ahead.
Prescription Growth ConcernsThis is the first time repeat prescriptions have surpassed new prescriptions, potentially indicating a slowdown in new start growth.
Research And Development CostsThe higher R&D spend this quarter, driven by manufacturing expenses for subq Briumvi, also raised some eyebrows.